Study on the Effects of Ranibizumab in Glaucoma Surgery
Author Information
Author(s): Frank Bochmann, Claude Kaufmann, Christoph Becht, Ivo Guber, Michael Kaiser, Lucas M Bachmann, Michael A Thiel
Primary Institution: Department of Ophthalmology, Lucerne Cantonal Hospital, Lucerne, Switzerland
Hypothesis
Can topical ranibizumab improve outcomes in glaucoma filtration surgery?
Conclusion
Topical ranibizumab may help prevent scarring and has fewer side effects compared to traditional treatments.
Supporting Evidence
- Ranibizumab is an anti-VEGF drug that may reduce scarring after glaucoma surgery.
- Previous studies have shown that anti-VEGF treatments can improve wound healing.
- Topical application of ranibizumab is expected to have fewer side effects than systemic treatments.
Takeaway
This study is testing if a special eye drop can help people who have surgery for glaucoma by preventing scarring.
Methodology
The study has two phases: the first assesses safety in 5 patients, and the second compares ranibizumab to placebo in 50 patients.
Potential Biases
Potential bias in patient selection and treatment allocation.
Limitations
The study may not account for all variables affecting surgery outcomes.
Participant Demographics
Patients aged 18 and older with primary open angle glaucoma, excluding those with previous surgeries or certain conditions.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website